We serve N,N-Dimethyl (octan/decan)amides CAS:308062-09-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | Colorless to light yellow liquid | Conform |
| Color | ≤1.0 | 0.3 |
| Purity | ≥98.0% | 98.32% |
| Acid value | ≤4 mgKOH/g | 1.8 mgKOH/g |
| Free amine | ≤0.1% | 0.05% |
| Moisture | ≤0.3% | 0.2% |
| Components | Amide C8:50-62% Amide C10:38-50% |
C8:58.01% C10:40.31% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like N,N-Dimethyl (octan/decan)amides chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-Dimethyl (octan/decan)amides physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N-Dimethyl (octan/decan)amides Use and application,N,N-Dimethyl (octan/decan)amides technical grade,usp/ep/jp grade.
Related News: The policy-oriented emphasis on the medical and pharmaceutical industries and the direct support for the chemical raw material pharmaceutical industry have created a good political environment for the development of related enterprises and laid the foundation for the rapid development of the chemical raw material pharmaceutical industry. The good development prospects of the chemical raw material pharmaceutical industry will be passed directly to the upstream raw material industry, which will help stimulate the demand for the pharmaceutical intermediate market.5-ethyl-1-methyl-2-(4-methyl-styryl)-pyridinium manufacturer The Philippines reported its first Wuhan coronavirus fatality on Sunday.(S)-3-Mercapto-2-{(2S,3S)-2-[(E)-3-((S)-2-mercapto-1-methoxycarbonyl-2-methyl-propylamino)-2-phenylacetylamino-acryloyloxy]-4-oxo-3-phenylacetylamino-azetidin-1-yl}-3-methyl-butyric acid methyl ester supplier Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Poly[oxycarbonyl-1,4-phenylene[(1R)-1-hydroxy-2-methylene-1,4-butanediyl]] vendor Matthew Cheung, Hong Kong’s No. 2 official, appealed to medical workers to reconsider. “At this critical moment, I believe the general public would count on medical personnel to fight against the epidemic together, in the spirit of professionalism,” he wrote in a blog post on Sunday.As of Friday, the virus had claimed the lives of more than 250 people in mainland China.
